Abstract 5119
Background
Bone marrow trephine biopsy (BMTB) is the gold standard test for identification of marrow infiltration by lymphoma. Literature supports the use of bilateral iliac crest biopsy for appropriate staging of lymphoma.18F-FDG PET/CT has an advantage of evaluating the entire skeleton for bone or bone marrow (BM) uptake. We calculated the predictive values of PET/CT in detecting the BM infiltration in lymphoma patients. We also assessed the increment in the yield of bilateral BMTB over unilateral BMTB in detecting BM infiltration by lymphoma.
Methods
This study is a retrospective and prospective single center observational study done in tertiary care hospital in Chandigarh, India. The study included 230 newly diagnosed lymphoma patients who underwent both baseline staging PET CT and staging bilateral Bone Marrow Trephine Biopsy (BMTB). The bone marrow trephine biopsy slides were reviewed independently by two experienced pathologists (one hematopathologist and one histopathologist).
Results
Table: 1013PD
The sensitivity, specificity, PPV and NPV of 18-FDG PET/CT in detecting BM infiltration in patients with lymphoma
| Diagnosis | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|
| All Subtypes | 59% | 65% | 38% | 81% |
| HL | 81% | 58% | 31% | 93% |
| NHL | 54% | 67% | 40% | 77% |
| HG-NHL | 58% | 62% | 35% | 81% |
| LG-NHL | 43% | 84% | 63% | 70% |
The incremental yield of diagnosing BM infiltration by lymphoma by doing bilateral posterior superior iliac spine biopsies over unilateral biopsy was 25% for all subtype of lymphoma and 57% for HL. The most common pattern of BM infiltration was nodular (37%), followed by diffuse (22%), para-trabecular (21%) and interstitial (20%) in the whole study cohort. There was a strong aggreement between the two pathologists in reporting BMTB. The accuracy of SUVmax in differentiating patients with and without true BM involvement in our study cohort was less than optimal.
Conclusions
Opting for unilateral trephine biopsy for lymphoma staging may lead to inadvertent under-staging, especially in Hodgkin Lymphoma. We may consider avoiding bone marrow biopsy in patients with Hodgkin Lymphoma with no FDG avid skeletal lesions in PET/CT. The BMTB has got a high reproducibility and lesser inter observer variability in detection of bone marrow infiltration by lymphoma.
Clinical trial identification
Legal entity responsible for the study
PGIMER, Chandigarh.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3336 - CD13 and CD33 CAR-T cells for the treatment of myeloid malignancies.
Presenter: Koon Lee
Session: Poster Discussion session - Haematological malignancies
Resources:
Abstract
5735 - The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS
Presenter: Hind Medyouf
Session: Poster Discussion session - Haematological malignancies
Resources:
Abstract
2782 - ALK positive Anaplastic large cell lymphoma: molecular diagnosis and minimal residual disease monitoring
Presenter: Marketa Kalinova
Session: Poster Discussion session - Haematological malignancies
Resources:
Abstract
3796 - Intensified 14 day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP14) compared to RCHOP21 in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Presenter: Jose Sandoval-Sus
Session: Poster Discussion session - Haematological malignancies
Resources:
Abstract
2417 - Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Presenter: Martin Dreyling
Session: Poster Discussion session - Haematological malignancies
Resources:
Abstract
2586 - Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies
Presenter: Wojceich Jurczak
Session: Poster Discussion session - Haematological malignancies
Resources:
Abstract
4219 - A prospective study of first-line Helicobacter pylori eradication therapy in treating localized extragastric mucosa-associated lymphoid tissue lymphoma
Presenter: Sung-Hsin Kuo
Session: Poster Discussion session - Haematological malignancies
Resources:
Abstract
2563 - Bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan for relapsed follicular lymphoma; a preliminary analysis of a multicenter, prospective phase II study (BRiZ2012).
Presenter: Masatoshi Kanno
Session: Poster Discussion session - Haematological malignancies
Resources:
Abstract
Poster Discussion session - Haematological malignancies - Invited Discussant 1014PD, 1015PD and 1016PD
Presenter: Michele Ghielmini
Session: Poster Discussion session - Haematological malignancies
Resources:
Slides
Webcast
Poster Discussion session - Haematological malignancies - Invited Discussant 1008PD and 1009PD
Presenter: Marion Subklewe
Session: Poster Discussion session - Haematological malignancies